Policy
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Frontage Holdings Corporation, the parent company of Frontage Laboratories, Inc., a fast-growing contract research organization, specializing in R&D product development services, with operations in both the United States and China, announced on May 30th that the Company’s Shares have initiated trading on the Main Board of The Stock Exchange of Hong Kong.
Accsense Monitoring System Automates Data Archive and Alarming
Nivolumab plus ipilimumab meet primary endpoint of MD Anderson NEOSTAR Phase II trial
Last year, China invested $2.8 billion in U.S. health care companies, a big jump from the $702.9 million in 2017.
Help us identify the leading employers in the life science industry! We want to uncover who leads in key areas like diversity, culture, unique benefits and, of course, who are the 2019 Life Sciences Ideal Employers.
Medtronic plc announced U.S. Food and Drug Administration clearance and commercial launch for the SelectSite C304-HIS deflectable catheter system for use in procedures involving His-bundle pacing.
The collaboration will establish a study protocol with an initial focus on breast cancer to provide the regulatory agency with information on the evolving treatment landscape, including insight on treatment variation within defined subpopulations of patients with the disease.
TARA Biosystems, Inc. announced the execution of an exclusive worldwide license agreement with Columbia University for intellectual property relating to engineered human heart tissues.
There are approximately 11 million adults in the U.S. living with bipolar disorder, a condition that causes extreme shifts in mood, energy and activity levels.
The approval of Piqray combined with fulvestrant is the first FDA-approved treatment for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer.